Germline predictors of androgen deprivation therapy response in advanced prostate cancer

Mayo Clinic Proceedings

Volumn 87, Issue 3, 2012, Pages 240-246

  Kohli, Manish ^a   Riska, Shaun M ^a   Mahoney, Douglas W ^a   Chai, High S ^a   Hillman, David W ^a   Rider, David N ^a   Costello, Brian A ^a   Qin, Rui ^a   Lamba, Jatinder ^b   Sahasrabudhe, Deepak M ^c   Cerhan, James R ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; GLYCINE; GONADORELIN;

ADULT; ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CYP19A1 GENE; DRUG EFFECT; DRUG TREATMENT FAILURE; FOLLOW UP; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GERM LINE; HSD17B12 GENE; HSD17B4 GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; OUTCOME ASSESSMENT; PHENOTYPIC VARIATION; PREDICTION; PRMT3 GENE; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SREBF2 GENE; TREATMENT DURATION; TRMT11 GENE; TUMOR GENE;

EID: 84857980986     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2011.09.009     Document Type: Article

References (28)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol. 1997;79(2):235-246.
3. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321(7):419-424. (Pubitemid 19211484)
4. Denis LJ, Keuppens F, Smith PH, et al; EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. Eur Urol. 1998;33(2):144-151.
5. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339(15):1036-1042. (Pubitemid 28457865)
6. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 2000;355(9214):1491-1498.
7. Ross RW, Xie W, Regan MM, et al. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer. 2008;112(6):1247-1253. (Pubitemid 351429739)
8. Altekruse SF, Kosary CL, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute; 2010. http://seer.cancer.gov/csr/1975-2007/. Accessed June 1, 2011.
9. Ross RW, Oh WK, Xie W, et al. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2008;26(6):842-847. (Pubitemid 351398074)
10. Sun T, Lee GS, Werner L, et al. Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. Cancer Epidemiol Biomarkers Prev. 2010;19(7):1871-1878.
11. Sharifi N, Hamada A, Sissung T, et al. A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int. 2008;102(5):617-621.
12. Yang M, Xie W, Mostaghel E, et al. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011;29(18):2565-2573.
13. Ghayee HK, Auchus RJ. Clinical implications of androgen synthesis via 5alpha-reduced precursors. Endocr Dev. 2008;13:55-66.
14. Auchus RJ. The backdoor pathway to dihydrotestosterone. Trends Endocrinol Metab. 2004;15(9):432-438. (Pubitemid 39440726)
15. Sicotte H, Rider DN, Poland GA, Dhiman N, Kocher JP. SNPPicker: high quality tag SNP selection across multiple populations. BMC Bioinformatics. 2011;12:129.
16. Gauderman WJ, Murcray C, Gilliland F, Conti DV. Testing association between disease and multiple SNPs in a candidate gene. Genet Epidemiol. 2007;31(5):383-395. (Pubitemid 47051001)
17. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc B. 1995;57:289-300.
18. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110(7):1493-1500. (Pubitemid 47463063)
19. Keating NL, O'Malley AJ, Freeland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(1):4448-4456. (Pubitemid 46630983)
20. Sato N, Akakura K, Isaka S, et al; Chiba Prostate Study Group. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Urology. 2004;64(2):341-345. (Pubitemid 39092467)
21. Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2010;57(1):49-59.
22. Palmberg C, Koivisto P, Visakorpi T, Tammela TL. PSA decline is an independent prognostic marker in hormonally treated prostate cancer. Eur Urol. 1999;36(3):191-196. (Pubitemid 29381303)
23. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787-790.
24. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27(23):3742-3728.
25. Vasaitis TS, Bruno RD, Njar VC. CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol. 2011;125(1-2):23-31.
26. Kohli M, Tindall DJ. New developments in the medical management of prostate cancer. Mayo Clin Proc. 2010;85(1):77-86.
27. Bugano DD, Conforti-Froes N, Yamaguchi NH, Baracat EC. Genetic polymorphisms, the metabolism of estrogens and breast cancer: a review. Eur J Gynaecol Oncol. 2008;29(4):313-320.
28. Ji Y, Olson J, Zhang J, et al. Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms. Cancer Res. 2008;68(14):5997-6005.